We are live on !
Find out more
Superstring Capital Management Portfolio holdings
AUM
$158M
Turnover
44.19%
1-Year Est. Return
418.32%
This Fund
S&P 500
This Quarter Est. Return
+58.52%
1 Year Est. Return
+418.32%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$114M
AUM Growth
+$34.9M
(+44%)
Cap. Flow
+$19.5M
Cap. Flow % of AUM
Cap. Flow %
17.09%
Top 10 Holdings %
Top 10 Hldgs %
76.05%
Holding
48
New
9
Increased
7
Reduced
9
Closed
20
Avg Time Held
Equity + Options
0.3
years
Top 10 Avg Time Held
Equity + Options
0.2
years
Top 20 Avg Time Held
Equity + Options
0.3
years
Avg Time Held Equity only
0.3
years
Top 10 Avg Time Held Equity only
0.2
years
Top 20 Avg Time Held Equity only
0.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oric Pharmaceuticals
ORIC
|
+$9.39M |
| 2 |
Structure Therapeutics
GPCR
|
+$8.78M |
| 3 |
Zai Lab
ZLAB
|
+$7.78M |
| 4 |
NovoCure
NVCR
|
+$5.91M |
| 5 |
Tango Therapeutics
TNGX
|
+$4.61M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Legend Biotech
LEGN
|
+$5.02M |
| 2 |
Keros Therapeutics
KROS
|
+$3.39M |
| 3 |
Arcellx
ACLX
|
+$3.26M |
| 4 |
Arrowhead Research
ARWR
|
+$2.89M |
| 5 |
BeOne Medicines Ltd
ONC
|
+$1.78M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.89% |
| 2 | Miscellaneous | 2.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Zai Lab
ZLAB
$3.04B
| $15.1M | 13.25% |
626,932
+411,754
| +191% | +$7.78M |
2024 Q2
1 quarter
|
|
2
Cytokinetics
CYTK
$7.82B
| $11.4M | 9.97% |
215,798
+28,165
| +15% | +$1.57M |
2023 Q4
3 quarters
|
|
3
DELISTED
Terns Pharmaceuticals
TERN
| $11.2M | 9.84% |
1,348,546
+392,004
| +41% | +$3.23M |
2024 Q2
1 quarter
|
|
|
4
Structure Therapeutics
GPCR
$1.42B
| $10M | 8.72% |
+227,047
| New | +$8.78M |
2024 Q3
0 quarters
|
|
|
5
Oric Pharmaceuticals
ORIC
$818M
| $9.7M | 8.52% |
+949,522
| New | +$9.39M |
2024 Q3
0 quarters
|
|
6
Instil Bio
TIL
$40.9M
| $7.24M | 6.34% |
+107,545
| New | +$2.53M |
2024 Q3
0 quarters
|
|
|
7
NovoCure
NVCR
$1.37B
| $6.14M | 5.37% |
392,711
+325,819
| +487% | +$5.91M |
2024 Q2
1 quarter
|
|
8
BridgeBio Pharma
BBIO
$15.2B
| $5.77M | 5.05% |
226,684
+6,847
| +3% | +$180K |
2023 Q4
3 quarters
|
|
9
Fate Therapeutics
FATE
$156M
| $5.13M | 4.49% |
1,466,934
+969,574
| +195% | +$3.77M |
2023 Q4
3 quarters
|
|
10
Capricor Therapeutics
CAPR
$556M
| $5.13M | 4.49% |
+337,347
| New | +$1.67M |
2024 Q3
0 quarters
|
|
|
11
Tango Therapeutics
TNGX
$4.29B
| $4.61M | 4.04% |
599,048
+483,477
| +418% | +$4.61M |
2024 Q2
1 quarter
|
|
12
DELISTED
89bio
ETNB
| $4.4M | 3.86% |
595,203
-85,200
| -13% | -$716K |
2023 Q4
3 quarters
|
|
13
Nkarta
NKTX
$85.2M
| $3.35M | 2.93% |
740,294
-135,705
| -15% | -$771K |
2023 Q4
3 quarters
|
|
|
14
Legend Biotech
LEGN
$3.39B
| $2.95M | 2.58% |
60,515
-94,150
| -61% | -$5.02M |
2024 Q2
1 quarter
|
|
|
15
CALL
Zai Lab
ZLAB
$3.04B
| $2.41M | 2.11% |
+100,000
| New | +$1.89M |
2024 Q3
0 quarters
|
|
16
Zenas BioPharma
ZBIO
$1.9B
| $1.89M | 1.65% |
+111,605
| New | +$2.01M |
2024 Q3
0 quarters
|
|
17
Allogene Therapeutics
ALLO
$290M
| $1.34M | 1.17% |
478,115
-211,797
| -31% | -$565K |
2023 Q4
3 quarters
|
|
18
Spyre Therapeutics
SYRE
$9.8B
| $1.1M | 0.96% |
37,287
-8,284
| -18% | -$231K |
2024 Q2
1 quarter
|
|
19
Savara
SVRA
$1.04B
| $848K | 0.74% |
200,000
| – | – |
2023 Q4
3 quarters
|
|
20
Biomea Fusion
BMEA
$42.3M
| $844K | 0.74% |
83,554
-83,556
| -50% | -$543K |
2024 Q2
1 quarter
|
|
21
DELISTED
Tourmaline Bio
TRML
| $748K | 0.65% |
29,104
-66,125
| -69% | -$1.1M |
2024 Q1
2 quarters
|
|
22
Zura Bio
ZURA
$119M
| $636K | 0.56% |
156,626
| – | – |
2024 Q2
1 quarter
|
|
23
Cabaletta Bio
CABA
$278M
| $622K | 0.54% |
131,795
-8,100
| -6% | -$46.9K |
2024 Q1
2 quarters
|
|
24
Corbus Pharmaceuticals
CRBP
$70.5M
| $524K | 0.46% |
25,401
-31,067
| -55% | -$1.59M |
2024 Q2
1 quarter
|
|
25
Immunovant
IMVT
$7.07B
| $355K | 0.31% |
+12,447
| New | +$367K |
2024 Q3
0 quarters
|
|
Similar funds
JAIC
Superstring Capital Management's Q3 2024 Portfolio in Review
As of Q3 2024, Superstring Capital Management held 48 positions worth $114M, up 44% from $79.3M the previous quarter. Its ten largest holdings account for 76% of the portfolio.
Superstring Capital Management deployed $19.5M of net new capital in Q3 2024, opening 9 new positions and adding to 7 existing holdings. Its largest new stake was Oric Pharmaceuticals: 949,522 shares worth $9.7M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Legend Biotech, an estimated $5.02M trimmed.
- Superstring Capital Management's largest Q3 2024 buy was Oric Pharmaceuticals: 949,522 shares worth $9.7M.
- Superstring Capital Management added most to Zai Lab in Q3 2024, an estimated $7.78M increase.
- Superstring Capital Management's biggest Q3 2024 reduction was Legend Biotech, cutting an estimated $5.02M.
- Superstring Capital Management fully exited Keros Therapeutics in Q3 2024, selling an estimated $3.39M.
- Superstring Capital Management's ten largest holdings make up 76% of its $114M portfolio in Q3 2024.
- Superstring Capital Management opened 9 new positions and closed 20 in Q3 2024.
- Superstring Capital Management's portfolio value rose 44% quarter-over-quarter to $114M.
Based on Superstring Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.